Pro-Dex Q3 Results: Revenue Growth Continues, Margin Pressures Persist

What happened

Pro-Dex reported fiscal 2026 third quarter results with net sales growing double-digits year-over-year, driven by continued shipments of the next-generation orthopedic handpiece to its largest customer, which accounted for 75% of revenue. However, gross margin remained under pressure from tariff costs, under-absorption of manufacturing overhead, and weaker repair margins, consistent with previous quarters. Operating cash flow turned modestly positive after a negative fiscal 2025, but inventory levels stayed elevated at around $22 million, limiting free cash flow generation. The company maintained its contractual minimums with the key OEM through 2027, but cancelable purchase orders and customer concentration leave revenue visibility imperfect. Overall, the results align with the base-case scenario of mid-single-digit earnings growth, but do not yet resolve the fundamental tension between top-line momentum and bottom-line volatility.

Implication

Over the next 6-12 months, investors should monitor whether gross margin can stabilize above 27-28% and operating cash flow turns consistently positive. If margins remain below 25% for two more quarters, the thesis weakens and the stock could drift toward the bear-case $30. Conversely, sustained margin improvement above 28% with positive free cash flow could re-rate the stock toward the bull-case $52. Given the lack of clear near-term catalysts, patience is rewarded.

Thesis delta

The Q3 report confirms the base case of steady revenue growth but does not yet provide the margin stabilization or cash flow inflection needed to upgrade the thesis. The thesis shifts from 'wait for evidence' to 'continue waiting' as the key metrics—gross margin and operating cash flow—remain mixed. Without a clear positive surprise, the stock is likely to trade in a narrow range until more quarters confirm a trend.